Haemoctin Sdh (Human Coagulation Factor Viii)

Haemoctin Sdh is indicated for the replacement of deficient factor VIII in several clinical situations.

• Routine prophylaxis to prevent bleeding episodes in patients with severe hemophilia A.
• On‑demand treatment of acute hemorrhage in hemophilia A.
• Surgical or invasive procedure coverage to maintain hemostasis in hemophilia A patients.
• Management of bleeding in von Willebrand disease type 3, which also lacks factor VIII.

Adverse reactions reported with Haemoctin Sdh reflect typical responses to factor VIII concentrates.

Common

• Headache.
• Fever.
• Nausea.
• Injection‑site erythema.
• Mild allergic rash.

Serious

• Anaphylactic reaction.
• Development of inhibitors (neutralizing antibodies).
• Thromboembolic events.
• Severe hypotension.
• Acute hemolysis (rare).

Before initiating therapy with Haemoctin Sdh, clinicians should evaluate several safety considerations.

• Assess patient history for prior inhibitor development.
• Verify absence of active infections, especially hepatitis B/C or HIV.
• Monitor for signs of hypersensitivity during and after infusion.
• Use caution in patients with cardiovascular disease due to potential thrombotic risk.
• Adjust dosage in pediatric patients based on weight and clinical response.
• Store product at recommended temperature to preserve activity.

Haemoctin Sdh may interact with other agents that affect hemostasis or immune response.

Avoid

• Concurrent use of other factor concentrates without medical oversight.
• High‑dose pro‑coagulant agents (e.g., activated factor VII) that could increase thrombosis risk.

Use with caution

• Immunosuppressive drugs that may alter inhibitor formation.
• Antifibrinolytics (e.g., tranexamic acid) when combined with factor VIII therapy.
• Vaccines administered shortly before or after infusion may affect immune response.